Abivax S.A. buy melinda
Start price
21.12.17
/
50%
€8.60
Target price
21.06.18
€15.00
Performance (%)
-19.53%
End price
21.06.18
€6.92
Summary
This prediction ended on 21.06.18 with a price of €6.92. The price of Abivax S.A. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -19.53%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Abivax S.A. | - | - | - | - |
iShares Core DAX® | 0.039% | 0.567% | 12.281% | 14.748% |
iShares Nasdaq 100 | -4.018% | -5.554% | 23.851% | 36.769% |
iShares Nikkei 225® | -2.389% | -1.434% | 8.335% | 5.073% |
iShares S&P 500 | -2.115% | -2.351% | 22.061% | 37.971% |
According to melinda what are the pros and cons of Abivax S.A. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by melinda for this prediction
In the thread Abivax S.A. diskutieren
Biotechnologie und Medizintechnik SecteurRecherche Agenda 16/03 Ergebnisse Veröffentlichung
![logo Abivax Logo Abivax](http://logos.cofisem.fr/FR0012333284.jpg)
Anzahl der Mitarbeiter: 23 Personen.
(Laufzeit überschritten)
Stopped prediction by melinda for Abivax S.A.
Abivax S.A.
Start price
Target price
Perf. (%)
€9.10
04.08.22
04.08.22
-
04.08.23
04.08.23
81.32%
05.08.23
05.08.23
Could be very worthwhile Investment >20% year
Abivax S.A.
Start price
Target price
Perf. (%)
€9.85
07.11.19
07.11.19
€28.00
04.11.21
04.11.21
184.77%
05.11.21
05.11.21
Could be very worthwhile Investment >20% year
Abivax S.A.
Start price
Target price
Perf. (%)
€11.04
27.01.19
27.01.19
€16.00
29.07.19
29.07.19
-13.50%
29.07.19
29.07.19
Could be very worthwhile Investment >20% year
Abivax S.A.
Start price
Target price
Perf. (%)
€6.00
17.02.17
17.02.17
€10.00
03.04.17
03.04.17
17.33%
03.04.17
03.04.17
Could be very worthwhile Investment >20% year
Abivax S.A.
Start price
Target price
Perf. (%)
€10.80
26.04.16
26.04.16
€20.00
26.10.16
26.10.16
-29.35%
26.10.16
26.10.16
Could be very worthwhile Investment >20% year